Wyeth-Ayerst Premarin delta 8,9 component should be classified as active ingredient -- amended petition.
Executive Summary
WYETH-AYERST PREMARIN DELTA 8,9-DHES SHOULD BE CONSIDERED ACTIVE INGREDIENT, "the same as estrone sulfate and equilin sulfate," the company says in a recent letter to FDA amending its November 1994 citizen petition. In defining the components of Premarin, a February 1991 Generic Drugs Advisory Committee classified delta 8,9-dehydroestrone sulfate as a signal impurity, subject to a limit test. Wyeth-Ayerst's contention since then has been that delta 8,9-DHES should be reclassified as a required "concomitant component."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth